Gettysburg, PA, Sept. 05, 2017 (GLOBE NEWSWIRE) -- The risk of relapse is great for those diagnosed with schizophrenia, with the 1-year rate as high as 50% and the 5 year rate as high as 80% – making long-term therapy goals difficult to reach.1,2 In 2010, there were over 397,000 hospital stays for schizophrenia and other psychotic disorders and of those, approximately 1 in 4 (22%) were readmitted within 30 days.3 Patient wellness, reducing severity of symptoms, and reduced risk of future relapses are critical therapy outcomes.4,5
Just as significant is the cost of mental health care and treatment services which are estimated at $113 billion annually. The cost increases to $300 billion annually when you add in the cost of lost earnings and wages, and disability benefits.4 The direct costs for schizophrenia in the U.S. were estimate at $47 billion (in 2013 dollars).6
Join Heidi Waters, PhD, Director of Outcomes Management at Otsuka Pharmaceutical Development & Commercialization, Inc. and co-presenter, Annie Medina, MBA, ACNP-BC, Senior Associate at OPEN MINDS, for this session to learn about the Frameworks In Health & Quality disease management program focusing on schizophrenia relapse reduction. In this session, faculty will discuss a program and strategies for relapse reduction with topics including:
- Current trends in population health management and health system services for the management of schizophrenia
- Models for improving outcome of consumers with schizophrenia through medication adherence, medication reconciliation, and transition of care support
- Education support resources for all stakeholders involved in the management of schizophrenia
The co-presenter is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc.
To learn more about this executive web briefing or to take advantage of the free online registration, please visit: https://www.openminds.com/event/consumers-schizophrenia-tools-relapse-reduction/.
All registrants will receive a recording of the webinar and an electronic copy of the presentation slides at its conclusion. The recording is at no charge and is not subject to attendance.
1.Schennach R. et al. Psychiatry SeN. 2012: 63(1):87-90.
2. Robinson D. et al. Arch Gen Psychiatry. 1999: 56(3):241-247.
3. Elixhauser A. Steiner C. Readmissions to U.S. Hospitals by Diagnosis. 2010. HCUP Statistical Stief #153. April 2013. Ag en Of fOf Healthcare Research and Quality. Rockville MD. http://hcup-us.ahrq.gov/repocts.statbfiefs/sb 153.pdf. Accessed January 27 2014.
4. Lehman AF et al. Practice Guideline for the Treatment of Patients with Schizophrenia. JI. Formulation and Implementation of a Treatment P lan. Arlington, VA : American Psychiatric Publishing. Inc.: 2004.
5. Faltai P. et al. World J Biol Psychiatry. 2006: 7(1): 5–40.
6. Cloutier M. et al. J Clin Psychiatry. 2016: TT(6): 764-TT1.
*****
About The Frameworks In Health & Quality Program
At Otsuka, we are passionate about making a difference in the lives of people suffering with serious mental illness, cancer, and other serious health conditions. That is why, in addition to our medicines, we offer educational resources and disease management programs to help key stakeholders improve quality of care for patients.
The Frameworks in Health and Quality programs are born out of Otsuka’s dedication to provide leading insights in the diseases we treat and education about optimal management of these diseases. Each program provides a set of educational resources for payers, members of care teams, and patients and their caregivers. These resources emphasize patient wellness and educate about the disease and ways to manage it. Learn more at https://frameworkshealth.org/.
Frameworks resources are intended for informational purposes only and are intended for healthcare professional. They are not intended as, nor are they a substitute for, medical care, advice, or professional diagnosis. Healthcare professionals should use their independent medical judgement when considering Framework educational resources. Users seeking medical advice should consult with a health care professional. Frameworks resources are not intended as reimbursement or legal advice. You should seek independent, qualified professional advice to ensure that your organization is in compliance with the complex legal and regulatory requirements governing health care services, and that treatment decisions are made consistent with the applicable standards of care.
*****
About OPEN MINDS
OPEN MINDS is an award-winning information source, executive education provider, and business solutions firm specializing in the post-acute health and human service markets. For thirty years, we’ve been pioneers for change – helping organizations implement the transformational business practices they need to succeed in an evolving market with new policies and regulations.
OPEN MINDS is powered by a national team of experienced executives and subject matter experts with specific expertise in the post-acute health care market. Our mission is to improve the quality of care for individuals with complex support needs by improving the effectiveness of those serving them – provider organizations, payer and insurance organizations, government agencies, pharmaceutical organizations, and technology firms. Learn more at www.openminds.com.
© 2017 Otsuka Pharmaceutical Development & Commercialization, Inc. MRC2.UNB.X.00147